Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

OBJECTIVENivolumab plus ipilimumab (NIVO + IPI) and pembrolizumab plus axitinib (PEM + AXI) have demonstrated significant clinical benefits as first-line (1 L) treatments for intermediate/poor-risk advanced renal cell carcinoma (aRCC) patients. This study aimed to assess the cost-effectiveness of NI...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical economics 2023-12, Vol.26 (1), p.1108-1121
Hauptverfasser:	Dhanji, Nishit, Decimoni, Tassia Cristina, Dyer, Matthew T. D., May, Jessica R., van de Wetering, Gijs, Petersohn, Svenja, Nickel, Katharina, Silva, Amanda, Muniz, David Q. B., Casagrande D. Oliveira, Ana Paula
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!